|
1
|
Modelling of atherosclerosis in genetically modified animals.
Mushenkova NV, Summerhill VI, Silaeva YY, Deykin AV, Orekhov AN.
Am J Transl Res. 2019 Aug 15;11(8):4614-4633. eCollection 2019.
|
|
2
|
Heteroplasmic Variants of Mitochondrial DNA in Atherosclerotic Lesions of Human Aortic Intima.
Sobenin IA, Zhelankin AV, Khasanova ZB, Sinyov VV, Medvedeva LV, Sagaidak MO, Makeev VJ, Kolmychkova KI, Smirnova AS, Sukhorukov VN, Postnov AY, Grechko AV, Orekhov AN.
Biomolecules. 2019 Sep 6;9(9). pii: E455. doi: 10.3390/biom9090455.
|
|
3
|
Creation of Cybrid Cultures Containing mtDNA Mutations m.12315G>A and m.1555G>A, Associated with Atherosclerosis.
Sazonova MA, Sinyov VV, Ryzhkova AI, Sazonova MD, Khasanova ZB, Shkurat TP, Karagodin VP, Orekhov AN, Sobenin IA.
Biomolecules. 2019 Sep 18;9(9). pii: E499. doi: 10.3390/biom9090499.
|
|
4
|
Trained Circulating Monocytes in Atherosclerosis: Ex Vivo Model Approach.
Nikiforov NG, Wetzker R, Kubekina MV, Petukhova AV, Kirichenko TV, Orekhov AN.
Front Pharmacol. 2019 Jun 27;10:725. doi: 10.3389/fphar.2019.00725. eCollection 2019.
|
|
5
|
The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis.
Summerhill VI, Grechko AV, Yet SF, Sobenin IA, Orekhov AN.
Int J Mol Sci. 2019 Jul 20;20(14). pii: E3561. doi: 10.3390/ijms20143561.
|
|
6
|
Modern approaches for modelling dystonia and Huntington's disease in vitro and in vivo.
Zhunina OA, Yabbarov NG, Orekhov AN, Deykin AV
Int J Exp Pathol. 2019 Apr;100(2):64-71. doi: 10.1111/iep.12320. Epub 2019 May 15.
|
|
7
|
An update on the tools for creating transgenic animal models of human diseases - focus on atherosclerosis.
Volobueva AS1, Orekhov AN2,3,4, Deykin AV2.
Braz J Med Biol Res. 2019;52(5):e8108. doi: 10.1590/1414-431X20198108. Epub 2019 Apr 25.
|
|
8
|
Inhibitors of DNA methylation and histone deacetylation as epigenetically active drugs for anticancer therapy.
Myasoedova VA, Grechko AV, Zhang D, Orekhov AN.
Curr Pharm Des. 2019 Apr 5. doi: 10.2174/1381612825666190405144026. [Epub ahead of print]
|
|
9
|
Trans-sialidase associated with atherosclerosis : defining the identity of a key enzyme involved in the pathology.
Glanz VY, Myasoedova VA, Grechko AV, Orekhov AN.
Curr Drug Targets. 2019 Mar 7. doi: 10.2174/1389450120666190308111619. [Epub ahead of print]
|
|
10
|
Human disease modelling techniques: current progress.
Glanz VY, Orekhov AN, Deykin AV.
Curr Mol Med. 2019 Feb 6. doi: 10.2174/1566524019666190206204357.
|
